Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis
| Autor: | Mads Lamm Larsen, Steen Dalby Kristensen, Anne-Mette Hvas, Erik Lerkevang Grove, Søren Bønløkke, Peter Buur van Kooten Niekerk, Oliver Heidmann Pedersen |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Time Factors platelet turnover thrombocytosis Coronary Artery Disease 030204 cardiovascular system & hematology Gastroenterology INTERINDIVIDUAL VARIABILITY 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine WHOLE-BLOOD Medicine Humans Platelet Dosing Prospective Studies CYCLOOXYGENASE INHIBITION Whole blood Aspirin THROMBOXANE BIOSYNTHESIS Thrombocytosis essential thrombocythemia business.industry Essential thrombocythemia Anti-Inflammatory Agents Non-Steroidal LOW-DOSE ASPIRIN Hematology General Medicine ANTIPLATELET DRUGS Middle Aged medicine.disease PREVENTION Thromboxane B2 Regimen 030104 developmental biology chemistry CARDIOVASCULAR-DISEASE platelet aggregation thromboxane b(2) Female business RESISTANCE medicine.drug Thrombocythemia Essential |
| Zdroj: | Larsen, M L, Pedersen, O H, Hvas, A-M, Niekerk, P B V K, Bønløkke, S, Kristensen, S D & Grove, E L 2019, ' Once-versus twice-daily aspirin treatment in patients with essential thrombocytosis ', Platelets, vol. 30, no. 3, pp. 322-328 . https://doi.org/10.1080/09537104.2018.1430356 |
| ISSN: | 1369-1635 |
| DOI: | 10.1080/09537104.2018.1430356 |
| Popis: | Insufficient platelet inhibition has been reported in up to 40% of aspirin-treated patients, including patients with essential thrombocytosis. To maintain sufficient platelet inhibition, a shorter dosing interval with aspirin has been suggested. We aimed to investigate the antiplatelet effect of low-dose aspirin given twice-daily compared to standard once-daily dosing in patients with essential thrombocytosis. We included 22 patients, who were treated for 7 days with standard once-daily aspirin (75 mg once-daily) followed by 7 days treatment of twice-daily aspirin (37.5 mg twice-daily). The two regimens were separated by 14 days aspirin washout. Blood samples were obtained 1h and 24h/12h after the last pill intake in each regimen. The effect of aspirin was evaluated by: (1) platelet aggregation measured by whole blood impedance aggregometry (Multiplate® Analyser) using arachidonic acid (ASPItest 0.5 mM) as agonist and (2) serum thromboxane B2levels determined using an enzyme-linked immunosorbent assay. The difference in platelet aggregation from 1h to the end of the dosing interval (24h/12h) was used to compare the two regimens. We demonstrated a significantly smaller difference in platelet aggregation in the twice-daily regimen compared to the once-daily: mean of difference = 228 AU*min (95% confidence interval (CI): 92-363, p < 0.01). In addition, a significantly smaller difference in thromboxane B2was demonstrated in the twice-daily regimen compared to the once-daily regimen: mean of difference = 16.3 ng/mL (95% CI: 9.9-22.7, p < 0.01). In conclusion, twice-daily dosing with low-dose aspirin provides a more consistent platelet inhibition compared with standard once-daily dosing in patients with essential thrombocytosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|